EBITDA: Income before interest, taxes, depreciation and amortization.
Monopar Therapeutics Inc. (MNPR) had EBITDA of $-4.09M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-3.44M |
|
-- |
|
-- |
|
$4.09M |
|
$-4.09M |
|
$0.66M |
|
$-3.44M |
|
$-3.44M |
|
$-3.44M |
|
$-3.44M |
|
$-3.44M |
|
$-3.44M |
|
$-4.09M |
|
|
EBITDA |
$-4.09M |
7.12M |
|
7.12M |
|
$-0.48 |
|
$-0.48 |
|
| Balance Sheet Financials | |
$144.09M |
|
-- |
|
$0.11M |
|
$144.20M |
|
$2.57M |
|
-- |
|
$0.07M |
|
$2.64M |
|
$141.56M |
|
$141.56M |
|
$141.56M |
|
6.66M |
|
| Cash Flow Statement Financials | |
$-8.83M |
|
$-1.26M |
|
$91.96M |
|
$45.82M |
|
$127.68M |
|
$81.86M |
|
$3.73M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
56.10 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-8.83M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-2.43% |
|
-2.43% |
|
-2.38% |
|
-2.43% |
|
$21.25 |
|
$-1.24 |
|
$-1.24 |
|